Annexin Pharmaceuticals AB's total assets for Q4 2024 were kr19.04M, a decrease of -33.43% from the previous quarter. SE:ANNX total liabilities were kr5.32M for the fiscal quarter, a 51.57% a decrease from the previous quarter. See a summary of the company’s assets, liabilities, and equity.